Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, vol.136, pp.359-386, 2015. ,
Cancer statistics, CA Cancer J Clin, vol.66, pp.7-30, 2016. ,
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer, Cochrane Database Syst Rev, vol.005340, 2016. ,
Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer, Semin Oncol, vol.16, pp.83-97, 1989. ,
Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis, Eur J Surg Oncol, vol.41, pp.1578-1589, 2015. ,
Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy, J Gastrointest Oncol, vol.7, pp.45-57, 2016. ,
A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for a-and b-radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative, J Nucl Med, vol.53, pp.1951-1959, 2012. ,
Pharmacodynamic study of 131 Ilabeled CA215 antibody on an animal model of estrogen-resistant OC-3-VGH ovarian cancer, Exp Ther Med, vol.10, pp.572-578, 2015. ,
Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium177 in an ovarian cancer model, Eur J Nucl Med Mol Imaging, vol.41, pp.1907-1915, 2014. ,
L1-CAM-targeted antibody therapy and 177 Lu-radioimmunotherapy of disseminated ovarian cancer, Int J Cancer, vol.130, pp.2715-2721, 2012. ,
Senekowitsch-Schmidtke R. 177 Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213 Bi-immunotherapy, but causes toxicity not observed with 213 Bi, Eur J Nucl Med Mol Imaging, vol.38, pp.312-322, 2011. ,
Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials, MAbs, vol.2, pp.550-564, 2010. ,
, White blood cell count, hemoglobin level, and weight were monitored in healthy mice at various times from days 0 to 36 after IP-RIT and BIP-RIT with 177 Lu16F12 or 213 Bi-16F12 and expressed as ratio relative to treatment with NaCl control. (B) Wholebody PET/CT images of mice bearing subcutaneous AN3CA cell tumor xenografts in right flank at 24, 48, 72, FIGURE 7. (A) Hematologic toxicity, pp.89-105
177 Lu-labeled MOv18 as compared to 131 Ior 90 Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts, Nucl Med Biol, vol.36, pp.759-770, 2009. ,
Beta dose-rate distributions in microscopic spherical tumors for intraperitoneal radioimmunotherapy, Int J Radiat Oncol Biol Phys, vol.56, pp.1495-1506, 2003. ,
Indium-111-and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice, J Nucl Med, vol.39, pp.476-484, 1998. ,
Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis, Cancer Biother Radiopharm, vol.15, pp.53-64, 2000. ,
Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: effect of the radionuclide, Int J Gynecol Cancer, vol.13, pp.607-613, 2003. ,
Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose, J Nucl Med, vol.47, pp.1342-1350, 2006. ,
Comparison of therapeutic efficacy and biodistribution of 213 Bi-and 211 At-labeled monoclonal antibody MX35 in an ovarian cancer model, Nucl Med Biol, vol.39, pp.15-22, 2012. ,
Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model, Clin Cancer Res, vol.9, pp.3914-3921, 2003. ,
Model of intraperitoneal targeted a-particle therapy shows that posttherapy cold-antibody boost enhances microtumor radiation dose and treatable tumor sizes, J Nucl Med, vol.59, pp.646-651, 2018. ,
Therapeutic efficacy of alpharadioimmunotherapy with different activity levels of the 213 Bi-labeled monoclonal antibody MX35 in an ovarian cancer model, EJNMMI Res, vol.7, p.38, 2017. ,
Cure of human ovarian carcinoma solid xenografts by fractionated alpha-radioimmunotherapy with 211 At-MX35-F(ab9) 2 : influence of absorbed tumor dose and effect on long-term survival, J Nucl Med, vol.58, pp.598-604, 2017. ,
Comparison between internalizing antiHER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212 Pb, PLoS One, vol.8, p.69613, 2013. ,
Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125 I-labeled monoclonal antibodies, J Nucl Med, vol.51, pp.1748-1755, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00531603
Noninternalizing monoclonal antibodies are suitable candidates for 125 I radioimmunotherapy of small-volume peritoneal carcinomatosis, J Nucl Med, vol.50, pp.2033-2041, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00442929
Intraperitoneal radioimmunotherapy: Auger electron emitters for solid tumors, Immunotherapy, vol.3, pp.491-494, 2011. ,
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission, J Clin Oncol, vol.24, pp.571-578, 2006. ,
Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications, Endocr Rev, vol.22, pp.657-674, 2001. ,
Insensitivity to anti-Müllerian hormone due to a mutation in the human anti-Müllerian hormone receptor, Nat Genet, vol.11, pp.382-388, 1995. ,
Genetic studies of the AMH/MIS signaling pathway for Müllerian duct regression, Mol Cell Endocrinol, vol.211, pp.15-19, 2003. ,
Anti-Müllerian hormone is a specific marker of Sertoli-and granulosa-cell origin in gonadal tumors, Hum Pathol, vol.31, pp.1202-1208, 2000. ,
Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers, Gynecol Oncol, vol.108, pp.141-148, 2008. ,
The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia, Int J Oncol, vol.34, pp.1583-1591, 2009. ,
AAV9 delivering a modified human Müllerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer, Proc Natl Acad Sci USA, vol.112, pp.4418-4427, 2015. ,
The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand, Biochem J, vol.379, pp.785-793, 2004. ,
Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates, Nucl Med Biol, vol.26, pp.977-982, 1999. ,
Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine, Nat Protoc, vol.5, pp.739-743, 2010. ,
Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess, J Immunol Methods, vol.72, pp.77-89, 1984. ,
Comparing time activity curves using the Akaike information criterion, Phys Med Biol, vol.54, pp.501-507, 2009. ,
Society of Nuclear Medicine and Molecular Imaging, 1991. ,
Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters, Clin Cancer Res, vol.5, pp.3031-3043, 1999. ,
Society of Nuclear Medicine and Molecular Imaging, 2008. ,
Monte Carlo calculations of absorbed doses in tumours using a modified MOBY mouse phantom for preclinical dosimetry studies, Acta Oncol, vol.50, pp.973-980, 2011. ,
A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications, Med Phys, vol.41, p.64301, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01015819
Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates, Curr Radiopharm, vol.4, pp.321-328, 2011. ,
DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy, PLoS One, vol.9, p.88239, 2014. ,